Tavaborole

Source: Wikipedia, the free encyclopedia.
Tavaborole
Clinical data
Trade namesKerydin
Other namesAN2690
AHFS/Drugs.comMonograph
MedlinePlusa614049
Routes of
administration
Topical
ATC code
Legal status
Legal status
  • US: ℞-only
  • In general: ℞ (Prescription only)
Identifiers
  • 5-Fluoro-2,1-benzoxaborol-1(3H)-ol
JSmol)
  • B1(C2=C(CO1)C=C(C=C2)F)O
  • InChI=1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2
  • Key:LFQDNHWZDQTITF-UHFFFAOYSA-N

Tavaborole, sold under the brand name Kerydin, is a

protein synthesis. The inhibition of protein synthesis leads to termination of cell growth and then cell death
, eliminating the fungal infection.

Medical uses

Tavaborole is used in the treatment of onychomycosis. In clinical trials, tavaborole was more effective than the vehicle (ethyl acetate and propylene glycol) alone in curing onychomycosis. In two studies, fungal infection was eliminated using tavaborole in 6.5% of the cases vs. 0.5% using the vehicle alone, and 27.5% vs. 14.6% using the vehicle alone.[1]

Side effects

Application site exfoliation, erythema (rash), and irritation are possible side effects, and may occur in less than 5% of individuals.[1]

Pharmacology

Tavaborole acts as an inhibitor of fungal leucyl-tRNA synthetase.[3]

Pharmacokinetics

Tavaborole, when prepared with a 1:1 mixture of ethyl acetate and propylene glycol, has the ability to fully penetrate through the human nail.[citation needed] In studies with cadaver fingernails, a 5% solution of tavaborole penetrated the nail an average of 524.7 mcg/cm2 after two weeks of daily use.[1]

Tavaborole is detectable in the blood at a level of 3.54 ng/mL after a single use of 0.2 mL of the 5% solution. Tavaborole has an

elimination half-life of 28.5 hours, a maximum concentration of 5.17 ng/mL after two weeks of daily use, and takes 8 days to reach the maximum concentration.[1]

Society and culture

Economics

Tavaborole began phase III clinical trials in December 2010[4] and was approved by the US FDA in July 2014.[5]

Originally developed by

Anacor, it is now marketed in the United States by Novartis subsidiary Sandoz. Anacor was paid US$65 million and also entered into a profit sharing scheme for future sales.[6] A 10 mL bottle of a 5% solution of tavaborole will cost the patient without insurance about $1,356.[7]

See also

References

  1. ^
    PMID 25956661
    .
  2. ^ "FDA Approves Anacor Pharmaceuticals' KERYDIN™ (Tavaborole) Topical Solution, 5% for the Treatment of Onychomycosis of the Toenails". Market Watch. July 8, 2014.
  3. PMID 29547036
    .
  4. ^ Clinical trial number NCT01270971 for "Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail" at ClinicalTrials.gov
  5. ^ "FDA Approves Anacor Pharmaceuticals' KERYDIN™ (Tavaborole) Topical Solution, 5% for the Treatment of Onychomycosis of the Toenails". Market Watch. July 8, 2014.
  6. ^ "Anacor's Kerydin to Be Commercialized by Sandoz in the U.S." Zacks.com. 22 July 2014. Retrieved 7 October 2015.
  7. ^ "Kerydin". Retrieved 12 August 2015.

External links

  • "Tavaborole". Drug Information Portal. U.S. National Library of Medicine.